$MBRX
Moleculin Biotech, Inc.

2020 Q2 Form 10-Q Financial Statement

#000165961720000128 Filed on May 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.650M $1.810M $1.560M
YoY Change 11.49% 13.84% 13.87%
% of Gross Profit
Research & Development $3.329M $3.206M $3.200M
YoY Change 58.6% 9.35% 9.22%
% of Gross Profit
Depreciation & Amortization $52.00K $46.00K $50.00K
YoY Change 6.12% -4.17% 25.0%
% of Gross Profit
Operating Expenses $5.034M $5.062M $4.810M
YoY Change 38.6% 10.74% 10.83%
Operating Profit -$5.034M -$5.062M
YoY Change 38.6% 10.74%
Interest Expense -$5.100M $3.850M $1.010M
YoY Change -311.62% 626.42% -35.67%
% of Operating Profit
Other Income/Expense, Net $17.00K $5.000K $10.00K
YoY Change -150.0%
Pretax Income -$10.11M -$1.210M -$3.800M
YoY Change 728.69% -70.05% 36.2%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.11M -$1.209M -$3.800M
YoY Change 728.17% -70.08% 36.2%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.020M -$145.4K -$498.0K
COMMON SHARES
Basic Shares Outstanding 60.40M shares 53.23M shares 45.73M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.73M $11.65M $10.74M
YoY Change -10.53% 32.69% 50.63%
Cash & Equivalents $16.73M $11.65M $10.74M
Short-Term Investments
Other Short-Term Assets $436.0K $615.0K $529.0K
YoY Change -71.13% -25.9% -37.02%
Inventory
Prepaid Expenses $2.749M
Receivables $1.000K $1.000K
Other Receivables
Total Short-Term Assets $19.75M $13.79M $13.48M
YoY Change -2.24% 43.42% 69.1%
LONG-TERM ASSETS
Property, Plant & Equipment $238.0K $271.0K $316.0K
YoY Change -40.65% -37.12% -31.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.63M $11.69M $11.75M
YoY Change -0.18% 0.0% 1.21%
TOTAL ASSETS
Total Short-Term Assets $19.75M $13.79M $13.48M
Total Long-Term Assets $11.63M $11.69M $11.75M
Total Assets $31.38M $25.47M $25.24M
YoY Change -1.49% 19.6% 28.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.918M $1.206M $2.153M
YoY Change 52.59% -56.91% 72.79%
Accrued Expenses $1.821M $2.029M $1.417M
YoY Change 31.01% 62.19% -42.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.739M $3.235M $3.570M
YoY Change -61.02% -49.74% -7.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.01M $6.950M $6.090M
YoY Change 6964.71% 3761.11% 322.92%
Total Long-Term Liabilities $12.01M $6.950M $6.090M
YoY Change 6964.71% 3761.11% 322.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.739M $3.235M $3.570M
Total Long-Term Liabilities $12.01M $6.950M $6.090M
Total Liabilities $15.75M $10.18M $9.664M
YoY Change 61.35% 53.87% 81.89%
SHAREHOLDERS EQUITY
Retained Earnings -$50.90M -$40.80M -$39.56M
YoY Change 61.08% 34.21% 50.1%
Common Stock $66.49M $56.06M $55.10M
YoY Change 23.84% 24.43% 35.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.63M $15.29M $15.57M
YoY Change
Total Liabilities & Shareholders Equity $31.38M $25.47M $25.24M
YoY Change -1.49% 19.6% 28.85%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income -$10.11M -$1.209M -$3.800M
YoY Change 728.17% -70.08% 36.2%
Depreciation, Depletion And Amortization $52.00K $46.00K $50.00K
YoY Change 6.12% -4.17% 25.0%
Cash From Operating Activities -$4.940M -$4.300M -$4.680M
YoY Change -7.49% 11.78% 50.48%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $2.000K -$10.00K
YoY Change 100.0% -86.67% -91.67%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$20.00K -$2.000K -$10.00K
YoY Change 100.0% -86.67% -91.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.291M
YoY Change -4.08%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.01M $5.291M 0.000
YoY Change -34.49% -4.17% -100.0%
NET CHANGE
Cash From Operating Activities -4.940M -$4.300M -4.680M
Cash From Investing Activities -20.00K -$2.000K -10.00K
Cash From Financing Activities 10.01M $5.291M 0.000
Net Change In Cash 5.050M $914.0K -4.690M
YoY Change -49.14% -44.54% 221.23%
FREE CASH FLOW
Cash From Operating Activities -$4.940M -$4.300M -$4.680M
Capital Expenditures -$20.00K $2.000K -$10.00K
Free Cash Flow -$4.920M -$4.302M -$4.670M
YoY Change -7.69% 11.39% 56.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001659617
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
001-37758
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
MOLECULIN BIOTECH, INC.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4671997
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5300 Memorial Drive,
CY2020Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 950
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77007
CY2020Q1 dei City Area Code
CityAreaCode
713
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
300-5160
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020Q1 dei Trading Symbol
TradingSymbol
MBRX
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60403164 shares
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11649000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10735000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2138000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2749000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
13787000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
13484000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
271000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
316000 USD
CY2020Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
266000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
287000 USD
CY2020Q1 us-gaap Assets
Assets
25472000 USD
CY2019Q4 us-gaap Assets
Assets
25235000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1206000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2153000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2029000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1417000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3235000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3570000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
248000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
276000 USD
CY2020Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6697000 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5818000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
10180000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
9664000 USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53227700 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53227700 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45727700 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45727700 shares
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
46000 USD
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
56011000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55055000 USD
CY2020Q1 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
-2000 USD
CY2019Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
31000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40770000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39561000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15292000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25472000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25235000 USD
CY2020Q1 us-gaap Revenues
Revenues
0 USD
CY2019Q1 us-gaap Revenues
Revenues
0 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3206000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2932000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1810000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1591000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
46000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5062000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4571000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5062000 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-529000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4571000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3845000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000 USD
CY2019Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49930997 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29064913 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-33000 USD
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-11000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1242000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4052000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
46000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
397000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
348000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3845000 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-529000 USD
CY2020Q1 mbx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-99000 USD
CY2019Q1 mbx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
0 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-611000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-9000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-947000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1553000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
506000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1235000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4342000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3847000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5291000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5516000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5291000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5521000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33000 USD
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
914000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1648000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10735000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7134000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11649000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8782000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
1000 USD
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000 USD
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
41000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
709000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
566000 USD
CY2020Q1 mbx Number Of Drug Technologies
NumberOfDrugTechnologies
3 technology
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
397000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2020Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-33000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15292000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14272000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
617000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2019Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-11000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14682000 USD
CY2020Q1 mbx Numberof Drug Candidates
NumberofDrugCandidates
6 candidate
CY2020Q1 mbx Numberof Drug Candidates
NumberofDrugCandidates
6 candidate
CY2020Q1 mbx Number Of Cancer Treatment Approaches
NumberOfCancerTreatmentApproaches
3 approach
CY2020Q1 mbx Numberof Drugsin Clinical Trials
NumberofDrugsinClinicalTrials
2 drug
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40800000 USD
CY2020Q1 mbx Vendor Prepayment And Deposits
VendorPrepaymentAndDeposits
1372000 USD
CY2019Q4 mbx Vendor Prepayment And Deposits
VendorPrepaymentAndDeposits
1857000 USD
CY2020Q1 us-gaap Prepaid Insurance
PrepaidInsurance
150000 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
352000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000 USD
CY2020Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
10000 USD
CY2020Q1 us-gaap Other Assets Current
OtherAssetsCurrent
615000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
529000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2138000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2749000 USD
CY2020Q1 mbx Vendor Prepayment And Deposits Expansion Of Production Commitments
VendorPrepaymentAndDepositsExpansionOfProductionCommitments
1100000 USD
CY2019Q4 mbx Vendor Prepayment And Deposits Expansion Of Production Commitments
VendorPrepaymentAndDepositsExpansionOfProductionCommitments
1500000 USD
CY2020Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
300000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
300000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
397000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
348000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q1 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
623000 USD
CY2019Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
436000 USD
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
302000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
272000 USD
CY2020Q1 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
262000 USD
CY2019Q4 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
93000 USD
CY2020Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
225000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
99000 USD
CY2020Q1 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
219000 USD
CY2020Q1 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
212000 USD
CY2019Q4 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
201000 USD
CY2019Q4 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
49000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
107000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
79000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
164000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2029000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1417000 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
8000 USD
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
14000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
29000 USD
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6700000 shares
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 USD
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
7000 USD
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
5000 USD
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
10000 USD
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18400000 shares
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
33000 USD
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
8000 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
110000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
101000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
138000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
105000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
56000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
10000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
410000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
55000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
355000 USD

Files In Submission

Name View Source Status
0001659617-20-000128-index-headers.html Edgar Link pending
0001659617-20-000128-index.html Edgar Link pending
0001659617-20-000128.txt Edgar Link pending
0001659617-20-000128-xbrl.zip Edgar Link pending
a2020q1ex311-xnextgen.htm Edgar Link pending
a2020q1ex312-xnextgen.htm Edgar Link pending
a2020q1ex321-xnextgen.htm Edgar Link pending
a2020q1ex322-xnextgen.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbx-20200331.htm Edgar Link pending
mbx-20200331.xsd Edgar Link pending
mbx-20200331_cal.xml Edgar Link unprocessable
mbx-20200331_def.xml Edgar Link unprocessable
mbx-20200331_g1.jpg Edgar Link pending
mbx-20200331_htm.xml Edgar Link completed
mbx-20200331_lab.xml Edgar Link unprocessable
mbx-20200331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending